PharVision Advisers’s MediWound MDWD Stock Holding History

PharVision Advisers’s Portfolio MDWD Stock Details MDWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,064	Closed	-$352K	–	427
2025 Q4	$352K	Buy	+19,064	New	+$348K	0.18%	186

Other funds holding MDWD

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

YLHM

Yelin Lapidot Holdings Management Tel Aviv, Israel $527M AUM 50.16% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PharVision Advisers's MDWD Position: Q1 2026 in Review

PharVision Advisers sold out of MediWound (MDWD) in Q1 2026, closing a stake of 19,064 shares — an estimated $352K sold.

PharVision Advisers first reported a position in MDWD in Q4 2025 and held it in 1 quarter. The position peaked at $352K in Q4 2025. 76 funds tracked by Wall St. Rank hold MDWD as of Q1 2026.

PharVision Advisers reported no remaining MediWound position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 19,064 MediWound shares in Q1 2026, an estimated $352K.
PharVision Advisers first reported a position in MediWound in Q4 2025 and held it in 1 quarter.
PharVision Advisers's MediWound position peaked at $352K in Q4 2025.
76 funds tracked by Wall St. Rank held MediWound as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.